Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.